Breaking News Instant updates and real-time market news.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

10:54
10/07/16
10/07
10:54
10/07/16
10:54

Clovis selloff a buying opportunity, says SunTrust

SunTrust analyst Peter Lawson views today's selloff in shares of Clovis Oncology as a buying opportunity, saying today's concern "seems like noise." The analyst has a Buy rating on the stock with a $50 price target. Clovis is down 13%, or $4.64, to $31.13 but is well off the day's lows.

  • 07

    Oct

  • 06

    Nov

  • 23

    Feb

CLVS Clovis
$35.77

-1.51 (-4.05%)

10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital

TODAY'S FREE FLY STORIES

MSTX

Mast Therapeutics

$0.14

0.003 (2.22%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Mast Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MTSI

MACOM

$50.32

-3.52 (-6.54%)

, SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$50.32

-3.52 (-6.54%)

SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

NXST

Nexstar

$69.90

1 (1.45%)

TRCO

Tribune Media

$36.72

0.17 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

CLLS

Cellectis

$23.83

0.26 (1.10%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Cellectis management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 06

    Jun

RDHL

RedHill Biopharma

$10.29

0.0199 (0.19%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
RedHill Biopharma to host research and development day »

Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

RXDX

Ignyta

$9.20

0.25 (2.79%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Ignyta holds a conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

BGG

Briggs & Stratton

$25.14

0.09 (0.36%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 10

    May

GTN

Gray Television

$15.05

0.4 (2.73%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Gray Television management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 04

    May

SGM

Stonegate Mortgage

$7.96

-0.0059 (-0.07%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Stonegate Mortgage to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/21 EIA Natural…

CMRX

Chimerix

$6.09

-0.01 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Chimerix to hold an investor update webcast »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Pending Home Sales Index to be reported at 10:00 »

March Pending Home Sales…

RGLS

Regulus

$1.55

0.1 (6.90%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Regulus management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Berenberg to hold a conference »

U.K. Corporate Conference…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
The Food & Drug Law Institute to hold a conference »

Introduction to U.S. Drug…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/22 Jobless…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/23 Bloomberg…

LGF

Use LGF.A, LGF.B

, AMCX

AMC Networks

$60.25

0.65 (1.09%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
FBN Securities media/cable analyst holds an analyst/industry conference call »

Media. Cable &…

LGF

Use LGF.A, LGF.B

AMCX

AMC Networks

$60.25

0.65 (1.09%)

DISCA

Discovery

$29.39

0.1 (0.34%)

CBS

CBS

$66.91

0.5 (0.75%)

NFLX

Netflix

$150.17

-1.99 (-1.31%)

AMZN

Amazon.com

$909.29

1.67 (0.18%)

VIA.B

Symbol now VIAB

NLSN

Nielsen

$39.41

-0.57 (-1.43%)

SNI

Scripps Networks

$76.49

0.53 (0.70%)

TWX

Time Warner

$100.20

0.16 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 05

    Jun

  • 15

    Jun

MEOH

Methanex

$46.10

0.15 (0.33%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Methanex Corporation to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/26 Fed Balance…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/17 Money Supply…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

WWD

Woodward

$68.05

-0.11 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Woodward management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 09

    May

  • 11

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.